Phanes Therapeutics to Present First Clinical Data for Spevatamig in Metastatic Pancreatic Cancer at ASCO GI 2026
Key Insights
Phanes Therapeutics (search) will present Phase 1/2 study results of spevatamig (search) (PT886) combined with chemotherapy for frontline treatment of metastatic pancreatic ductal adenocarcinoma (search) at ASCO GI 2026.
This marks the first public release of clinical trial data from the company's ongoing U.S. multi-center TWINPEAK study evaluating the first-in-class bispecific antibody.
Spevatamig (search) targets claudin 18.2 (search) and CD47 (search) and has received FDA orphan drug designation and Fast Track designation for metastatic pancreatic adenocarcinoma treatment.
Phanes Therapeutics (search) announced it will present Phase 1/2 study results of spevatamig (search) (PT886) in combination with chemotherapy for frontline treatment of metastatic pancreatic ductal adenocarcinoma (search) (mPDAC) at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium on January 8-10, 2026 in San Francisco. This represents the first public release of clinical trial data from the company's ongoing U.S. multi-center study with spevatamig.
Study Details and Presentation
The presentation, titled "Phase 1/2 study of spevatamig (search) (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (search) (mPDAC)," will be delivered on January 9, 2026, from 11:30am-1pm PST during the Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract session. Dr. Anwaar Saeed from the University of Pittsburgh Medical Center serves as the first author of the study.
Novel Bispecific Antibody Mechanism
Spevatamig (search) is a first-in-class native IgG-like bispecific antibody targeting claudin 18.2 (search) and CD47 (search). The drug has received significant regulatory recognition, earning orphan drug designation for pancreatic cancer (search) treatment from the FDA in 2022 and Fast Track designation for patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024.
Clinical Development Program
The multi-center Phase 1/2 clinical trial of spevatamig (search) (NCT05482893), known as the TWINPEAK study, is currently evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of spevatamig in patients with advanced gastric, gastroesophageal junction, pancreatic ductal or biliary tract adenocarcinomas. The Phase 2 study of spevatamig has begun in China.
Strategic Partnerships
In 2023, Phanes entered into a clinical collaboration agreement with Merck (search) (known as MSD outside the US and Canada) to study spevatamig (search) in combination with Merck's anti-PD-1 (search) therapy, pembrolizumab, expanding the therapeutic potential of the bispecific antibody platform.
Company Pipeline and Technology
Phanes Therapeutics (search) is currently conducting three Phase 1/2 clinical trials, including the MORNINGSTAR study with its monoclonal antibody program mavrostobart (search), the TWINPEAK study with spevatamig (search), and the SKYBRIDGE study with peluntamig. Both spevatamig and peluntamig are first-in-class bispecific antibodies that have received orphan drug designations and Fast Track designations from the FDA.
The company has developed its pipeline using proprietary technology platforms: PACbody®, SPECpair®, and ATACCbody® to develop novel bispecific antibodies with increased stability and manufacturability, and reversible modulation of immune activity.